TG Therapeutics Inc (TGTX) was Initiated by SunTrust to “Buy” and the brokerage firm has set the Price Target at $18. SunTrust advised their investors in a research report released on May 27, 2016.
TG Therapeutics Inc closed down -0.03 points or -0.38% at $7.78 with 4,27,075 shares getting traded on Wednesday. Post opening the session at $7.84, the shares hit an intraday low of $7.7 and an intraday high of $7.94 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 20, 2016, Sean A Power (CFO, Secretary and Treasurer) sold 10,000 shares at $10.12 per share price. According to the SEC, on Jul 10, 2015, William James Kennedy (director) sold 17,000 shares at $17.08 per share price.
TG Therapeutics Inc. (TG) is a biopharmaceutical company focused on the acquisition development and commercialization of treatments for b-cell malignancies and autoimmune diseases. As of December 31 2014 TG had two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202 an orally available PI3K delta inhibitor. As of December 31 2014 both TG-1101 and TGR-1202 were in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop inhibitors of IRAK4 (interleukin-1 receptor-associated kinase 4) as well as an antibody research program to develop anti-PD-L1 and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies which were in pre-clinical development as of December 31 2014.